454 Attributes Decline in Q2 Revenues to Delays from Customers Awaiting GS FLX+ Upgrade
July 26, 2011
454 Attributes Decline in Q2 Revenues to Delays from Customers Awaiting GS FLX+ Upgrade
"Customers delayed purchases of reagents on the GS FLX system as they waited for their upgrade to GS FLX+," said 454 President and CEO Chris McLeod.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- As 454 Preps Launch of Sanger-Length Reads, Early Customers Highlight Utility for De Novo Assembly
May 24, 2011 / In Sequence - Roche Achieves Sequencing on Semiconductor Platform; Automating ePCR with Japanese Partner
January 22, 2013 / In Sequence - In Applied Science Restructuring, Roche Exits Microarrays, Bundles 'Sequencing Solutions,' R&D
June 12, 2012 / In Sequence - Paired Ends
July 19, 2011 / In Sequence - Roche's Sequencing Business Grows 12 Percent YTD as Applied Science Sales Shrink in Q3
October 19, 2010 / In Sequence